Contact

Our portfolio

Regenesance

Regenesance focuses on antibody engineering to treat neurodegenerative diseases and immune-mediated disorders. The company licenses its technology to Complement Pharma, aiming to develop therapies for conditions like ALS and multiple sclerosis. The company leverages groundbreaking research to improve patient outcomes.

  • Institute: Amsterdam UMC
Industry: Immunology, Therapeutics
  • Founding year: 2009
Visit website

Want to get in contact about Regenesance?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

PacingCure
Developing gene therapy solutions for heart rhythm disorders.
Kling Biotherapeutics
Discovering novel antibodies for cancer and infectious disease treatments.
AMI Pharma
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
Parkinnova Therapeutics
Developing novel treatments for Parkinson’s disease and dopamine disorders.
PacingCure
Developing gene therapy solutions for heart rhythm disorders.
Kling Biotherapeutics
Discovering novel antibodies for cancer and infectious disease treatments.
AMI Pharma
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
Parkinnova Therapeutics
Developing novel treatments for Parkinson’s disease and dopamine disorders.
Explore full AAV portfolio
Contact